T1	intervention 51 78	fulvestrant plus vandetanib
T2	eligibility 665 762	Postmenopausal patients with bone predominant, hormone-receptor-positive metastatic breast cancer
T4	outcome-Measure 911 924	uNTx response
T6	intervention-participants 1008 1017	Sixty-one
T7	control-participants 1052 1054	68
T8	total-participants 1069 1072	127
T9	outcome 1097 1110	uNTx response
T10	iv-bin-percent 1123 1127	66 %
T11	cv-bin-percent 1139 1143	54 %
T12	outcome 1209 1212	PFS
T13	outcome 1247 1249	OS
T18	outcome 1326 1348	clinical benefit rates
T19	iv-bin-percent 1354 1356	41
T20	cv-bin-percent 1361 1365	43 %
T21	outcome 1392 1414	Serious adverse events
T22	iv-bin-percent 1429 1434	3.3 %
T23	cv-bin-percent 1449 1454	5.9 %
T24	outcome 1526 1529	PFS
T25	outcome 1569 1571	OS
T5	outcome-Measure 956 959	PFS
T14	outcome-Measure 961 963	OS
T15	outcome-Measure 965 980	RECIST response
T16	outcome-Measure 982 993	pain scores
T17	outcome-Measure 998 1006	toxicity
T3	control 871 883	placebo (FP)
